NCT06992440View on ClinicalTrials.gov

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

September 30, 2030

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Empagliflozin 10 MG

10 mg tablet once daily

DRUG

Placebo

matching tablet once daily

Trial Locations (3)

21287

NOT_YET_RECRUITING

The Johns Hopkins Hospital, Baltimore

37232

NOT_YET_RECRUITING

Vanderbilt University Medical Center, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Gustavo A Heresi, MD, MS

OTHER